Clinical Trials Browser

Phase 1/2 × Dasatinib × Myeloid × Clear all

NCT04835584 2022-03-21

KRT-232 and TKI Study in Chronic Myeloid Leukemia

Phase 1/2 Recruiting

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01498445 2020-10-22

An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)

Phase 1/2 Terminated

32 enrolled 16 charts

MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02923986 2020-05-28

Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS

Phase 1/2 Withdrawn

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

NCT00337454 2011-04-14

Study of BMS-354825 in Subjects With CML Who Are Resistant to or Intolerant of Imatinib or Ph+All in Japan

Phase 1/2 Completed

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00482703 2010-12-17

A Study of Dasatinib in Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia

Phase 1/2 Completed

23 enrolled 21 charts

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01030718 2010-12-14

Rollover Study of BMS-354825 in Patients With CML and Ph+ALL

Phase 1/2 Completed

54 enrolled 30 charts

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive